Pregabalin: In the treatment of painful diabetic peripheral neuropathy

Drugs

Volumn 64, Issue 24, 2004, Pages 2813-2820

  Frampton, James E ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; PLACEBO; PREGABALIN;

ANALGESIC ACTIVITY; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DIABETIC NEUROPATHY; DIZZINESS; DRUG MECHANISM; DRUG TOLERABILITY; EYE DISEASE; HEADACHE; HUMAN; LIVER TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; PAIN ASSESSMENT; PERIPHERAL EDEMA; PHARMACODYNAMICS; REVIEW; SLEEP DISORDER; SOMNOLENCE; VISUAL IMPAIRMENT;

ANALGESICS, NON-NARCOTIC; CLINICAL TRIALS; DIABETIC NEUROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GAMMA-AMINOBUTYRIC ACID; HUMANS;

RODENTIA;

EID: 10844281006     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464240-00006     Document Type: Review

References (45)

1. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002 Nov-2002 31; 18 (6): 350-4
2. Spruce MC, Potter J, Coppini DV. The pathogenesis and management of painful diabetic neuropathy: a review. Diabet Med 2003; 20 (2): 88-98
3. US Food and Drug Administration. FDA approves drug for neuropathic pain associated with diabetes [online], Available from URL: http://www.fda.gov/bbs/ topics/news/2004/ NEW01113.html [Accessed 2004 Sep 7]
4. Backonja M. Managing painful diabetic neuropathy. Hosp Pract (Off Ed) 1999 Oct 15; 34 (11): 79-88
5. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003 Nov; 60 (11): 1524-34
6. Huckle R. Pregabalin (Pfizer). Curr Opin Investig Drugs 2004 Jan; 5 (1): 82-9
7. Lauria-Homer BA, Pohl RB. Pregabalin: a new anxiolytic. Expert Opin Investig Drugs 2003; 12 (4): 663-72
8. Bryans JS, Wustrow DJ. 3-Substituted GABA analogs with central nervous system activity: a review. Med Res Rev 1999; 19: 149-77
9. Nozaki-Taguchi N, Chaplan SR, Higuera ES, et al. Vincristine-induced allodynia in the rat. Pain 2001 Jul; 93 (1): 69-76
10. Field MJ, McCleary S, Hughes J, et al. Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain 1999 Mar; 80 (1-2): 391-8
11. Field MJ, Bramwell S, Hughes J, et al. Detection of static and dynamic components of mechanical allodynia in rat models of neuropathic pain: are they signalled by distinct primary sensory neurones? Pain 1999 Nov; 83 (2): 303-11
12. Wallin J, Cui JG, Yakhnitsa V, et al. Gabapentin and pregabalin suppress tactile allodynia and potentiate spinal cord stimulation in a model of neuropathy. Eur J Pain 2002; 6 (4): 261-72
13. Chen SR, Xu Z, Pan HL. Stereospecific effect of pregabalin on ectopic afferent discharges and neuropathic pain induced by sciatic nerve ligation in rats. Anesthesiology 2001 Dec; 95 (6): 1473-9
14. Field MJ, Oles RJ, Lewis AS, et al. Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol 1997 Aug; 121 (8): 1513-22
15. Hurley RW, Chatterjea D, Rose Feng M, et al. Gabapentin and pregabalin can interact synergistically with naproxen to produce antihyperalgesia. Anesthesiology 2002 Nov; 97 (5): 1263-73
16. Partridge BJ, Chaplan SR, Sakamoto E, et al. Characterisation of the effects of gabapentin and 3-isobutyl-gamma-aminobutyric acid on substance P-induced thermal hyperalgesia. Anesthesiology 1998 Jan; 88 (1): 196-205
17. Jun JH, Yaksh TL. The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat. Anesth Analg 1998 Feb; 86 (2): 348-54
18. Jones DL, Sorkin LS. Systemic gabapentin and S(+)-3-isobutyl-gamma- aminobutyric acid block secondary hyperalgesia. Brain Res 1998 Nov 9; 810 (1-2): 93-9
19. Field MJ, Holloman EF, McCleary S, et al. Evaluation of gabapentin and S-(+)-3-isobutylgaba in a rat model of postoperative pain. J Pharmacol Exp Ther 1997 Sep; 282 (3): 1242-6
20. Bialer M, Johannessen SI, Kupferberg HJ. et al. Progress report on new antiepileptic drugs: a summary of the fifth Eilat conference (EILAT V). Epilepsy Res 2001; 43: 11-58
21. Dooley DJ, Donovan CM, Meder WP, et al. Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked. Synapse 2002 Sep 1; 45 (3): 171-90
22. Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002 Feb; 42 (2): 229-36
23. Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat neocortex and hippocampal slices by gabapentin. Neurosci Lett 2001 Feb; 280 (2): 107-10
24. Taylor CP. Meeting report: the biology and pharmacology of calcium channel alpha2-delta proteins. Pfizer satellite symposium to the 2003 Society for Neuroscience Meeting. CNS Drug Rev 2004; 10 (2): 159-64
25. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003 Sep; 105 (1-2): 133-41
26. Corrigan BW, Pool WF, Posvar EL, et al. Metabolic disposition of pregabalin in healthy volunteers [abstract no. PI-68]. Clin Pharmacol Ther 2001 Feb; 69: P18
27. Bockbrader HN, Hunt T, Strand J, et al. Pregabalin pharmacokinetics and safety in healthy volunteers: results from two phase I studies [abstract no. P06.051]. Neurology 2000 Apr 11; 54 Suppl. 3: A421
28. Busch JA, Strand JC, Posvar EL, et al. Pregabalin (CI-1008) single-dose pharmacokinetics and safety/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses [abstract no. 2.108]. Epilepsia 1998; 39 Suppl. 6: 58
29. Corrigan B, Burger P, Bockbrader H. Population pharmacokinetics of pregabalin in healthy volunteers, renally impaired patients, and patients with chronic pain [abstract no. 786]. J Pain 2002 Apr; 3 Suppl. 1: 47
30. Randinitis EJ, Posvar EL, Alvey CW, et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003 Mar; 43 (3): 277-83
31. Bockbrader HN, Wesche D. Pharmacokinetic profile of pregabalin: results of a series of studies [abstract no. NR378]. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, 140
32. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004; 110: 628-38
33. Sharma U, Allen R, Glessner C, et al. Pregabalin effectively relieves pain in patients with diabetic peripheral neuropathy: study 1008-014 [abstract no. 686-P]. Diabetes 2000 May; 49 Suppl. 1: 167
34. Lesser H, Sharma U, Lamoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004
35. Strojek K, Floter T, Balkenohl M, et al. Pregabalin in the management of chronic neuropathic pain (NeP): a novel evaluation of flexible and fixed dosing [abstract no. 804]. Diabetes 2004; 53 Suppl. 2: 59
36. Toelle T, Versavel M, Glessner C, et al. A novel treatment for diabetic peripheral neuropathy: pregabalin dose and pain relief [abstract]. Anaesthesiology 2004 Oct 23; 101: A967
37. Sharma U, Glessner C, Moore J, et al. Two studies show pregabalin effectively relieves pain in patients with painful diabetic peripheral neuropathy (studies 1008-14/-29) [poster no. NP05]. 2nd World Congress of World Institute of Pain; 2004 Jun 27-30; Istanbul
38. Sharma U, Young J, Lamoreaux L, et al. Pregabalin effectively relieves pain in patients with painful diabetic peripheral neuropathy [abstract no. 322-OR]. Diabetes 2002 Jun; 51 Suppl. 2: 79-80
39. Sharma U, Iacobellis D, Glessner C, et al. Pregabalin improves sleep in neuropathic pain patients [abstract no. NR531 plus poster]. 153rd American Psychiatric Association Annual Meeting; 2000 May 13-18; Chicago, 201
40. Rowbotham M, Young J, Sharma U, et al. Pregabalin shows reduction in pain by day three of treatment [abstract no. 846]. J Pain 2003 Mar; 4 Suppl. 1: 63 plus poster presented the 22nd Annual Scientific Meeting of the American Pain Society; 2003 Mar 20-23; Chicago
41. Portenoy R, Sharma U, Young J, et al. Pregabalin sustains its efficacy as long-term maintenance therapy for neuropathic pain associated with diabetic neuropathy and postherpetic neuralgia [abstract no. 599-P]. Diabetes 2004 Jun; 53 Suppl. 2: 142
42. Farrar JT, Young Jr JP, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001 Nov; 94 (2): 149-58
43. Data on file, Pfizer, 2004
44. Pfizer Inc. Pfizer receives approval to market Lyrica for neuropathic pain and add-on epilepsy in Europe [online]. Available from URL: http://www.pfizer.com/are/news_releases/2004pr/ mn_2004_0706.html [Accessed 2004 Sep 28]
45. Pfizer Inc. Pfizer statement on regulatory status of Lyrica [online]. Available from URL: http://www.pfizer.com/are/ news_releases/2004pr/ mn_2004_0902.html [Accessed 2004 Sep 28]